BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Rhythm Metabolic draws $40M series A for rare obesity disorders
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Rhythm Metabolic draws $40M series A for rare obesity disorders
Aug. 14, 2015
By
Marie Powers
No Comments
Propelled by a $40 million series A, Rhythm Metabolic Inc. will seek to pick up the tempo for RM-493 (setmelanotide), a peptide melanocortin-4 (MC4) agonist designed to treat obesity caused by genetic deficiencies in the MC4 pathway.
BioWorld